These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15088769)

  • 41. Influenza surveillance.
    Pereira M; Assaad FA; Delon PJ
    Bull World Health Organ; 1978; 56(2):192-203. PubMed ID: 78771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selection of influenza vaccine strains and developing pandemic vaccines.
    Wood JM
    Vaccine; 2002 Dec; 20 Suppl 5():B40-4. PubMed ID: 12477418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
    Belshe R; Lee MS; Walker RE; Stoddard J; Mendelman PM
    Expert Rev Vaccines; 2004 Dec; 3(6):643-54. PubMed ID: 15606348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influenza vaccine: the challenge of antigenic drift.
    Carrat F; Flahault A
    Vaccine; 2007 Sep; 25(39-40):6852-62. PubMed ID: 17719149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell-based protein vaccines for influenza.
    Cox MM
    Curr Opin Mol Ther; 2005 Feb; 7(1):24-9. PubMed ID: 15732526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.
    Belongia EA; Kieke BA; Donahue JG; Greenlee RT; Balish A; Foust A; Lindstrom S; Shay DK;
    J Infect Dis; 2009 Jan; 199(2):159-67. PubMed ID: 19086915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The global state of influenza in children.
    Esposito S; Marchisio P; Principi N
    Pediatr Infect Dis J; 2008 Nov; 27(11 Suppl):S149-53. PubMed ID: 18955890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. WHO influenza vaccine technology transfer initiative: role and activities of the Technical Advisory Group.
    Francis DP; Grohmann G
    Vaccine; 2011 Jul; 29 Suppl 1():A45-7. PubMed ID: 21684429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Surveillance and prevention of influenza in Belgium].
    Yane F
    Rev Med Brux; 2001 Sep; 22(4):A353-7. PubMed ID: 11680200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines.
    O'Neill E; Donis RO
    Curr Top Microbiol Immunol; 2009; 333():83-108. PubMed ID: 19768401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. World Vaccine Congress Lyon - Terrapinn's 11th Annual Congress.
    Sovran L
    IDrugs; 2009 Dec; 12(12):738-41. PubMed ID: 19943212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.
    Hampson AW; Osterhaus AD; Pervikov Y; Kieny MP
    Vaccine; 2006 Jun; 24(23):4897-4900. PubMed ID: 16823947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pandemic preparedness and the Influenza Risk Assessment Tool (IRAT).
    Cox NJ; Trock SC; Burke SA
    Curr Top Microbiol Immunol; 2014; 385():119-36. PubMed ID: 25085014
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consultation with directors of WHO collaborating centres on influenza: memorandum from a WHO meeting.
    Bull World Health Organ; 1988; 66(4):457-8. PubMed ID: 3262446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of laboratories in the WHO Eastern Mediterranean Region to the selection of candidate seasonal influenza vaccine, 2010-2015.
    Asghar H; Browne HM; McCauley J; Malik M; Khan W
    East Mediterr Health J; 2016 Oct; 22(7):445-452. PubMed ID: 27714738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A global pandemic influenza vaccine action plan.
    Kieny MP; Costa A; Hombach J; Carrasco P; Pervikov Y; Salisbury D; Greco M; Gust I; LaForce M; Franco-Paredes C; Santos JI; D'Hondt E; Rimmelzwaan G; Karron R; Fukuda K
    Vaccine; 2006 Sep; 24(40-41):6367-70. PubMed ID: 17240560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Models for predicting the evolution of influenza to inform vaccine strain selection.
    Agor JK; Özaltın OY
    Hum Vaccin Immunother; 2018 Mar; 14(3):678-683. PubMed ID: 29337643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.